Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies
10.3760/cma.j.issn.0253-2727.2018.06.003
- VernacularTitle: 抗CD19 CAR-T细胞治疗难治复发B细胞肿瘤10例临床分析
- Author:
Fang BAO
1
;
Kai HU
;
Wei WAN
;
Lei TIAN
;
Hongmei JING
Author Information
1. Department of Hematology, Peking University Third Hospital, Beijing 100083, China
- Publication Type:Journal Article
- Keywords:
Anti-CD19 CAR-T cell;
B cell hematological malignancies;
Treatment outcomes
- From:
Chinese Journal of Hematology
2018;39(6):454-459
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the outcomes of anti-CD19 CAR-T cell for relapsed and refractory B cell malignancies.
Method:Ten patients with relapsed and refractory B cell acute lymphocytic leukemia (B-ALL) and non-Hodgkin’s lymphoma (NHL), diagnosed in the Department of Hematology of Peking University third Hospital from December 2015 to July 2017, were treated with anti-CD19 CAR-T cell therapy, and the efficacy and safety were analyzed.
Results:Efficacy was assessed on the 28th day after cell infusion, including 66.7% (4/6) of complete remission (CR) for patients with ALL, 16.7% (1/6) of partial remission (PR), and 83.3% (5/6) of overall response rate (ORR). For NHL patients, CR was 33.3% (1/3) and most of the lesions disappeared in a patient with mantle cell lymphoma, but residual lesion presented persistent state. After infusion of anti-CD19 CAR-T cells, the main side effect was cytokine release syndrome (CRS) and fever. One patient presented with aphasia and the other one had multiple organ failure, which were improved after treatment. No patients died of CRS.
Conclusion:anti-CD19 CAR-T cell for relapsed and refractory B cells hematological malignancies is safe, and the most problematic side effect is CRS, which can be controlled by therapy.
